Reposted by Alexius John
Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...
nature.com
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer - Nature Medicine
Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that mol...